How soon will new “immune therapies” become mainstream? (https://www.myeloma.org/videos/how-soon-will-new-immune-therapies-become-mainstream)
|
In this week’s video, Dr. Brian G.M. Durie discusses the pros and cons of newer “immune therapies,” including monoclonal antibodies, checkpoint inhibitors, bispecific antibodies, and CAR-T cells. BOTTOM LINE:
|
|||
|
If you have a question that you’d like to suggest for a future episode of Ask Dr. Durie, please submit it to [email protected] (mailto:[email protected]). To reach the IMF InfoLine Coordinators, please call 800.452.2873 or email them at [email protected] (mailto:[email protected]). > |
Dr. Brian G.M. Durie serves as Chairman of the International Myeloma Foundation and serves on its Scientific Advisory Board. Additionally, he is Chairman of the IMF's International Myeloma Working Group, a consortium of nearly 200 myeloma experts from around the world. Dr. Durie also leads the IMF’s Black Swan Research Initiative®.